Immune Checkpoints and Innate Lymphoid Cells—New Avenues for Cancer Immunotherapy
Immune checkpoints (IC) are broadly characterized as inhibitory pathways that tightly regulate the activation of the immune system. These molecular “brakes” are centrally involved in the maintenance of immune self-tolerance and represent a key mechanism in avoiding autoimmunity and tissue destructio...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-11-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/13/23/5967 |
| _version_ | 1797507975788625920 |
|---|---|
| author | Nicolas Jacquelot Maryam Ghaedi Kathrin Warner Douglas C. Chung Sarah Q. Crome Pamela S. Ohashi |
| author_facet | Nicolas Jacquelot Maryam Ghaedi Kathrin Warner Douglas C. Chung Sarah Q. Crome Pamela S. Ohashi |
| author_sort | Nicolas Jacquelot |
| collection | DOAJ |
| description | Immune checkpoints (IC) are broadly characterized as inhibitory pathways that tightly regulate the activation of the immune system. These molecular “brakes” are centrally involved in the maintenance of immune self-tolerance and represent a key mechanism in avoiding autoimmunity and tissue destruction. Antibody-based therapies target these inhibitory molecules on T cells to improve their cytotoxic function, with unprecedented clinical efficacies for a number of malignancies. Many of these ICs are also expressed on innate lymphoid cells (ILC), drawing interest from the field to understand their function, impact for anti-tumor immunity and potential for immunotherapy. In this review, we highlight ILC specificities at different tissue sites and their migration potential upon inflammatory challenge. We further summarize the current understanding of IC molecules on ILC and discuss potential strategies for ILC modulation as part of a greater anti-cancer armamentarium. |
| first_indexed | 2024-03-10T04:56:03Z |
| format | Article |
| id | doaj.art-418a372f30934f589bebf77ff6cdedc8 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T04:56:03Z |
| publishDate | 2021-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-418a372f30934f589bebf77ff6cdedc82023-11-23T02:12:18ZengMDPI AGCancers2072-66942021-11-011323596710.3390/cancers13235967Immune Checkpoints and Innate Lymphoid Cells—New Avenues for Cancer ImmunotherapyNicolas Jacquelot0Maryam Ghaedi1Kathrin Warner2Douglas C. Chung3Sarah Q. Crome4Pamela S. Ohashi5Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, CanadaPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, CanadaPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, CanadaPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, CanadaDepartment of Immunology, University of Toronto, Toronto, ON M5S 1A8, CanadaPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, CanadaImmune checkpoints (IC) are broadly characterized as inhibitory pathways that tightly regulate the activation of the immune system. These molecular “brakes” are centrally involved in the maintenance of immune self-tolerance and represent a key mechanism in avoiding autoimmunity and tissue destruction. Antibody-based therapies target these inhibitory molecules on T cells to improve their cytotoxic function, with unprecedented clinical efficacies for a number of malignancies. Many of these ICs are also expressed on innate lymphoid cells (ILC), drawing interest from the field to understand their function, impact for anti-tumor immunity and potential for immunotherapy. In this review, we highlight ILC specificities at different tissue sites and their migration potential upon inflammatory challenge. We further summarize the current understanding of IC molecules on ILC and discuss potential strategies for ILC modulation as part of a greater anti-cancer armamentarium.https://www.mdpi.com/2072-6694/13/23/5967cancerinnate lymphoid cellsnatural killer cellsimmunotherapyimmune checkpointsmigration |
| spellingShingle | Nicolas Jacquelot Maryam Ghaedi Kathrin Warner Douglas C. Chung Sarah Q. Crome Pamela S. Ohashi Immune Checkpoints and Innate Lymphoid Cells—New Avenues for Cancer Immunotherapy Cancers cancer innate lymphoid cells natural killer cells immunotherapy immune checkpoints migration |
| title | Immune Checkpoints and Innate Lymphoid Cells—New Avenues for Cancer Immunotherapy |
| title_full | Immune Checkpoints and Innate Lymphoid Cells—New Avenues for Cancer Immunotherapy |
| title_fullStr | Immune Checkpoints and Innate Lymphoid Cells—New Avenues for Cancer Immunotherapy |
| title_full_unstemmed | Immune Checkpoints and Innate Lymphoid Cells—New Avenues for Cancer Immunotherapy |
| title_short | Immune Checkpoints and Innate Lymphoid Cells—New Avenues for Cancer Immunotherapy |
| title_sort | immune checkpoints and innate lymphoid cells new avenues for cancer immunotherapy |
| topic | cancer innate lymphoid cells natural killer cells immunotherapy immune checkpoints migration |
| url | https://www.mdpi.com/2072-6694/13/23/5967 |
| work_keys_str_mv | AT nicolasjacquelot immunecheckpointsandinnatelymphoidcellsnewavenuesforcancerimmunotherapy AT maryamghaedi immunecheckpointsandinnatelymphoidcellsnewavenuesforcancerimmunotherapy AT kathrinwarner immunecheckpointsandinnatelymphoidcellsnewavenuesforcancerimmunotherapy AT douglascchung immunecheckpointsandinnatelymphoidcellsnewavenuesforcancerimmunotherapy AT sarahqcrome immunecheckpointsandinnatelymphoidcellsnewavenuesforcancerimmunotherapy AT pamelasohashi immunecheckpointsandinnatelymphoidcellsnewavenuesforcancerimmunotherapy |